Drug recall · January 31, 2018
bupPROPion HCL Extended-Release Tablets recall
Why: Failed Impurities/Degradation Specifications: Mylan Pharmaceuticals Inc. is conducting a voluntary recall due to related out of specification compound results obtained during routine stability testing.
Class III: unlikely to cause harm, but breaks the rules (for example a labeling error).
The recall
- Product
bupPROPion HCL Extended-Release Tablets, USP (XL) 300 mg, 500-count bottle, Rx only, Mylan Pharmaceuticals Inc. Morgantown, WV 26505 U.S.A. NDC: 0378-2009-05
- Lots / codes
Lot # 3077281, EXP 06-2018
- Quantity
- 1,414/500 count bottles
- Company
- Mylan Pharmaceuticals Inc., Morgantown, WV
- Distribution
- Product was distributed nationwide in the USA
- Initiated
- November 3, 2017 · Voluntary: Firm initiated
- Classified
- January 19, 2018
- Reported
- January 31, 2018
- Ended
- June 14, 2018
- How notified
- Letter
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.